These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29773319)

  • 21. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.
    Sharma R; Mody N; Agrawal U; Vyas SP
    Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma.
    Yellu MR; Engel JM; Ghose A; Onitilo AA
    Hematol Oncol; 2016 Mar; 34(1):2-8. PubMed ID: 25524637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aptamers and their applications in nanomedicine.
    Sun H; Zu Y
    Small; 2015 May; 11(20):2352-64. PubMed ID: 25677591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
    Shi J; Xiao Z; Kamaly N; Farokhzad OC
    Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomedicine in veterinary oncology.
    Lin TY; Rodriguez CO; Li Y
    Vet J; 2015 Aug; 205(2):189-97. PubMed ID: 25862394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
    Muchtar E; Magen H; Gertz MA
    Leuk Lymphoma; 2017 Jun; 58(6):1283-1296. PubMed ID: 27734720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of multiple myeloma in Asia: resource-stratified guidelines.
    Tan D; Chng WJ; Chou T; Nawarawong W; Hwang SY; Chim CS; Chen W; Durie BG; Lee JH
    Lancet Oncol; 2013 Nov; 14(12):e571-81. PubMed ID: 24176575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biocompatible polymersomes-based cancer theranostics: Towards multifunctional nanomedicine.
    Mohammadi M; Ramezani M; Abnous K; Alibolandi M
    Int J Pharm; 2017 Mar; 519(1-2):287-303. PubMed ID: 28115259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Necessary diagnostic requirements and therapeutic recommendations in multiple myeloma].
    Jurczyszyn A; Zaucha JM; Machaczka M; Grosicki S; Dybko J; Czepiel J; Charliński G; Janda K; Knopińska-Posłuszny W; Skotnicki AB
    Przegl Lek; 2013; 70(9):744-53. PubMed ID: 24455837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
    Overchuk M; Zheng G
    Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
    Merz M; Hillengass J; Goldschmidt H
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):247-51. PubMed ID: 26068597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy.
    Shen S; Liu M; Li T; Lin S; Mo R
    Biomater Sci; 2017 Jul; 5(8):1367-1381. PubMed ID: 28664207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Review on High-Risk Multiple Myeloma.
    Chan HSH; Chen CI; Reece DE
    Curr Hematol Malig Rep; 2017 Apr; 12(2):96-108. PubMed ID: 28317082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomaterial applications in multiple sclerosis inflamed brain.
    Ballerini C; Baldi G; Aldinucci A; Maggi P
    J Neuroimmune Pharmacol; 2015 Mar; 10(1):1-13. PubMed ID: 25616566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in understanding multiple myeloma.
    Hari P
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):267-271. PubMed ID: 28633036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multiple myeloma: pathophysiology and progress in management].
    Kuroda J; Chinen Y
    Rinsho Ketsueki; 2017; 58(5):487-497. PubMed ID: 28592764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.